A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer
The purpose of this study is to determine the recommended phase 2 dose of LY3295668 erbumine in participants with platinum-sensitive, extensive-stage small-cell lung cancer.
Checked against the public recordLast updated Aug 5, 2021 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- Eli Lilly and Company
- Interventions being studied
- Drug: LY3295668 Erbumine
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Have histological or cytological evidence of a diagnosis of platinum sensitive small cell lung cancer that is extensive stage. * Have adequate organ function. * Have a performance status (PS) of ≤1 on the Eastern Cooperative Oncology Group (ECOG) scale. * Have discontinued previous treatments for cancer. * Are able to swallow capsules. Exclusion Criteria: * Currently enrolled in a clinical study. * Have a serious concomitant systemic disorder. * Have a symptomatic human immunodeficiency virus infection or symptomatic activated/reactivated hepatitis B or C. * Have a significant cardiac condition. * Have previously received an aurora kinase inhibitor.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Highlands Oncology GroupFayetteville, Arkansas
- Rocky Mountain Cancer CenterDenver, Colorado
- H Lee Moffitt Cancer CenterTampa, Florida
- Massachusetts General HospitalBoston, Massachusetts
- Dana Farber Cancer InstituteBoston, Massachusetts
- Washington University Medical SchoolSt Louis, Missouri
- Dartmouth Hitchcock Medical CenterLebanon, New Hampshire
- Memorial Sloan Kettering Cancer CenterNew York, New York
- Levine Cancer Institute- Carolinas Medical CenterCharlotte, North Carolina
- University of Pittsburgh Medical CenterPittsburgh, Pennsylvania
- Prisma Health Cancer InstituteGreenville, South Carolina
- Texas Oncology Cancer CenterAustin, Texas
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 5, 2021. Always confirm current availability with the study team.